2,716 Shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Purchased by XML Financial LLC

XML Financial LLC bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,716 shares of the specialty pharmaceutical company's stock, valued at approximately $337,000.

Other large investors have also bought and sold shares of the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $25,000. Quadrant Capital Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP raised its position in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $28,000. Finally, Allianz SE acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $29,000. 89.14% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on JAZZ shares. Morgan Stanley lowered their target price on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Truist Financial lifted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Needham & Company LLC reissued a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Barclays reaffirmed an "overweight" rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, HC Wainwright lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $184.00.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 500 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $107.90, for a total value of $53,950.00. Following the sale, the chief executive officer now directly owns 438,473 shares of the company's stock, valued at approximately $47,311,236.70. The trade was a 0.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Seamus Mulligan bought 1,621 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average cost of $103.00 per share, with a total value of $166,963.00. Following the completion of the purchase, the director now owns 101,621 shares in the company, valued at approximately $10,466,963. This trade represents a 1.62% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 3,000 shares of company stock worth $355,925 in the last 90 days. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Trading Down 0.6%

Jazz Pharmaceuticals stock traded down $0.61 during midday trading on Friday, hitting $106.90. 864,061 shares of the stock were exchanged, compared to its average volume of 827,221. The stock has a market capitalization of $6.47 billion, a PE ratio of 14.25, a P/E/G ratio of 4.62 and a beta of 0.33. The company has a fifty day simple moving average of $108.55 and a two-hundred day simple moving average of $119.66. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter last year, the business posted $2.68 earnings per share. The company's revenue for the quarter was down .5% on a year-over-year basis. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.